1-7 of 7
Cody J. Peer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82

Susana S. Najera, Christopher J. Ricketts, Laura S. Schmidt, Julia I. Medina, Keita Saito, Lilia Ileva, Jeffrey R. Brender, Amy M. James, Cody J. Peer, Brad Gouker, Baktiar O. Karim, Olga Chernova, Catherine Wells, Ming-Hui Wei, Youfeng Yang, Xiaohu Zhang, Carleen Klumpp-Thomas, Jameson Travers, Lu Chen, Kelli M. Wilson, Sameer H. Issaq, William D. Figg, Simone Difilippantonio, Joseph D. Kalen, Murali C. Krishna, Craig J. Thomas, Michele Ceribelli, Christine M. Heske, Daniel R. Crooks, Jordan L. Meier
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF14.
https://doi.org/10.1158/1535-7163.MCT-24-0225
Published: 06 November 2024
View article titled, Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Open the PDF for Targeting NAD<sup>+</sup> Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82 in another window
Includes: Supplementary data
Journal Articles

Abstract B047: Phase I trial of αvβ3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies

Nebojsa Skorupan, Cody J. Peer, Eve Koehler, Seth Steinberg, Jane B Trepel, William D Figg, Zhi-Ren Liu, Christine Alewine
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B047.
https://doi.org/10.1158/1535-7163.TARG-23-B047
Published: 01 December 2023
View article titled, Abstract B047: Phase I trial of αvβ3 integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies
Journal Articles

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

Natalia Garcia, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman, Cody J. Peer, William D. Figg, Myron S. Ignatius, Kris C. Wood, Peter J. Houghton, Angelina V. Vaseva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (1): 170–183.
https://doi.org/10.1158/1535-7163.MCT-21-0194
Published: 07 January 2022
View article titled, Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in <em>H/NRAS<sup>Q61X</sup></em> Mutant Rhabdomyosarcoma
Open the PDF for Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in <em>H/NRAS<sup>Q61X</sup></em> Mutant Rhabdomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Bih-Rong Wei, Shelley B. Hoover, Cody J. Peer, Jennifer E. Dwyer, Hibret A. Adissu, Priya Shankarappa, Howard Yang, Maxwell Lee, Tyler J. Peat, William D. Figg, R. Mark Simpson
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (11): 2308–2318.
https://doi.org/10.1158/1535-7163.MCT-19-0858
Published: 03 November 2020
View article titled, Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma
Open the PDF for Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Christine Alewine, Mehwish Iqra Ahmad, Cody J Peer, Seth Steinberg, William D Figg, Raffit Hassan, Ira Pastan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A081.
https://doi.org/10.1158/1535-7163.TARG-19-A081
Published: 01 December 2019
View article titled, Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion
Journal Articles

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Laetitia Marzi, Keli Agama, Junko Murai, Simone Difilippantonio, Amy James, Cody J. Peer, William D. Figg, Daniel Beck, Mohamed S.A. Elsayed, Mark Cushman, Yves Pommier
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (8): 1694–1704.
https://doi.org/10.1158/1535-7163.MCT-18-0028
Published: 31 July 2018
View article titled, Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors
Open the PDF for Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors in another window
Includes: Supplementary data
Journal Articles

Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues

Shaunna L. Beedie, Cody J. Peer, Steven Pisle, Erin R. Gardner, Chris Mahony, Shelby Barnett, Agnieszka Ambrozak, Michael Gütschow, Cindy H. Chau, Neil Vargesson, William D. Figg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (10): 2228–2237.
https://doi.org/10.1158/1535-7163.MCT-15-0320
Published: 05 October 2015
View article titled, Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues
Open the PDF for Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues in another window